Empirical Asset Management LLC Purchases 459 Shares of Medpace Holdings, Inc. $MEDP

Empirical Asset Management LLC boosted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 29.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,993 shares of the company’s stock after acquiring an additional 459 shares during the period. Empirical Asset Management LLC’s holdings in Medpace were worth $626,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Boston Trust Walden Corp increased its stake in Medpace by 12.1% during the 2nd quarter. Boston Trust Walden Corp now owns 151,074 shares of the company’s stock worth $47,416,000 after acquiring an additional 16,270 shares during the period. TD Asset Management Inc increased its stake in Medpace by 15.6% during the 2nd quarter. TD Asset Management Inc now owns 457,645 shares of the company’s stock worth $143,636,000 after acquiring an additional 61,764 shares during the period. Verdence Capital Advisors LLC increased its stake in Medpace by 5.7% during the 2nd quarter. Verdence Capital Advisors LLC now owns 1,049 shares of the company’s stock worth $329,000 after acquiring an additional 57 shares during the period. Vanguard Personalized Indexing Management LLC increased its stake in Medpace by 8.7% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 3,749 shares of the company’s stock worth $1,177,000 after acquiring an additional 299 shares during the period. Finally, Johnson Investment Counsel Inc. increased its stake in Medpace by 9.8% during the 2nd quarter. Johnson Investment Counsel Inc. now owns 1,647 shares of the company’s stock worth $517,000 after acquiring an additional 147 shares during the period. Institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Robert W. Baird raised their price objective on Medpace from $313.00 to $490.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 23rd. William Blair reiterated a “market perform” rating on shares of Medpace in a research note on Wednesday, July 23rd. Truist Financial lifted their price target on Medpace from $298.00 to $436.00 and gave the company a “hold” rating in a research note on Wednesday, July 23rd. Barclays lifted their price target on Medpace from $300.00 to $450.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 23rd. Finally, Jefferies Financial Group lifted their price target on Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a research note on Tuesday, September 9th. Two analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Medpace presently has a consensus rating of “Reduce” and an average target price of $424.10.

Insider Activity at Medpace

In related news, CEO August J. Troendle sold 36,196 shares of the firm’s stock in a transaction on Friday, August 29th. The stock was sold at an average price of $475.90, for a total transaction of $17,225,676.40. Following the sale, the chief executive officer owned 925,799 shares of the company’s stock, valued at $440,587,744.10. This trade represents a 3.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the firm’s stock in a transaction on Monday, July 28th. The shares were sold at an average price of $450.00, for a total value of $1,350,000.00. Following the sale, the general counsel directly owned 10,343 shares in the company, valued at approximately $4,654,350. This trade represents a 22.48% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 161,266 shares of company stock worth $74,111,427 over the last 90 days. 20.30% of the stock is currently owned by company insiders.

Medpace Stock Up 1.3%

NASDAQ MEDP opened at $521.21 on Friday. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $547.15. The company has a market cap of $14.64 billion, a price-to-earnings ratio of 38.75, a price-to-earnings-growth ratio of 3.23 and a beta of 1.40. The business’s fifty day moving average is $490.36 and its 200 day moving average is $380.24.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The company had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. During the same quarter last year, the business posted $2.75 EPS. Medpace’s revenue for the quarter was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.